Navigation Links
FORTUNE Magazine Ranks DaVita #1 Health Care Medical Facility in Innovation, Investment and Quality
Date:3/3/2009

Fourth Consecutive Year DaVita Ranks as One of the World's Most Admired Companies

EL SEGUNDO, Calif., March 3 /PRNewswire-FirstCall/ -- DaVita Inc., a leading provider of kidney care services, today accepted the honor by FORTUNE Magazine as one of the top health care facilities in the country. DaVita(R) ranked #1 in the field of Health Care Medical Facilities for innovation, Long-Term Investment and Quality of Products and Services. Overall, the company ranked 2nd in the Health Care Medical Facilities category and remains the only kidney care company to make FORTUNE Magazine's World's Most Admired Companies for list 2009. The recognition is awarded annually through FORTUNE Magazine, the definitive report card on corporate reputations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

"DaVita remains committed to shaping the future of health care through our unyielding commitment to quality clinical outcomes and chronic disease management. Our highest priority is delivering quality kidney care to our more than 110,000 patients," said Kent Thiry, DaVita Chairman and CEO. "Today's recognition that DaVita is #1 in Innovation, Long-Term Investment and Quality of Products and Services is a wonderful recognition for the work that has been done by so many of our teammates and nephrologist partners."

A total of 689 companies from 28 countries were surveyed for this year's list. The survey covers 64 industries: 25 international industries and 39 primarily U.S.-market industries. To create the 64 industry lists, executives, directors, and analysts were asked to rate companies in their own industry on nine criteria, from investment value to social responsibility. This year only the best are listed: A company's score must rank in the top half of its industry survey to be listed.'/>"/>

SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. BD Ranks 23rd on EPAs Fortune 500 List of Green Power Purchasers
2. Whole Foods Market(R) Makes FORTUNEs 100 Best Companies to Work For List for 12th Consecutive Year
3. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
4. Griffin Honored with Tenth Year on FORTUNE Best Companies to Work for List
5. Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company
6. Mesa Laboratories, Inc. Named to Fortune Small Business Magazines 2008 List
7. Registration Ends This Week: Fortune 500 Networking & Best Practice Sharing Conference in Florida
8. Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrows Leaders
9. Medco Tops Fortunes List of Americas Most Admired Companies in its Industry
10. Fortune 100 Companies Share Customer Experience Insights in Phoenix, Ariz., Feb. 25-27
11. Fortune 500 Executive Elected to AMA Board of Trustees
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3